Literature DB >> 15291864

The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Glenn S Gerber1, John M Fitzpatrick.   

Abstract

OBJECTIVE To examine the clinical profile of medication derived from a lipido-sterolic extract of Serenoa repens (saw palmetto) for managing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). METHODS We reviewed clinical trials involving extracts of S. repens, focusing on the benefit/risk ratio in patients with BPH. RESULTS S. repens extract significantly reduces the symptoms of BPH, increases urinary flow, improves the quality of life and is well tolerated. CONCLUSION Analysis of the overall clinical database indicates that extract of S. repens may be considered a viable first-line therapy for treating LUTS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15291864     DOI: 10.1111/j.1464-410X.2004.04962.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial.

Authors:  Gerald L Andriole; Christie McCullum-Hill; Gurdarshan S Sandhu; E David Crawford; Michael J Barry; Alan Cantor
Journal:  J Urol       Date:  2012-12-14       Impact factor: 7.450

2.  Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial.

Authors:  Nikolai Lopatkin; Andrey Sivkov; Sandra Schläfke; Petra Funk; Alexander Medvedev; Udo Engelmann
Journal:  Int Urol Nephrol       Date:  2007-02-15       Impact factor: 2.370

Review 3.  Pharmacological effects of saw palmetto extract in the lower urinary tract.

Authors:  Mayumi Suzuki; Yoshihiko Ito; Tomomi Fujino; Masayuki Abe; Keizo Umegaki; Satomi Onoue; Hiroshi Noguchi; Shizuo Yamada
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

4.  Analysis of the interactions of botanical extract combinations against the viability of prostate cancer cell lines.

Authors:  Lynn S Adams; Navindra P Seeram; Mary L Hardy; Catherine Carpenter; David Heber
Journal:  Evid Based Complement Alternat Med       Date:  2006-03       Impact factor: 2.629

5.  Biological diversity in the patent system.

Authors:  Paul Oldham; Stephen Hall; Oscar Forero
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.